Advertisement
Research Article

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

  • Thomas B. Campbell mail,

    thomas.campbell@ucdenver.edu

    Affiliation: Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, United States of America

    X
  • Laura M. Smeaton,

    Affiliation: Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, United States of America

    X
  • N. Kumarasamy,

    Affiliation: YRG Centre for AIDS Research & Education, Chennai, India

    X
  • Timothy Flanigan,

    Affiliation: Brown Medical School, Providence, Rhode Island, United States of America

    X
  • Karin L. Klingman,

    Affiliation: National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Cynthia Firnhaber,

    Affiliation: Clinical HIV Research Unit, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    X
  • Beatriz Grinsztejn,

    Affiliation: Evandro Chagas Clinical Research Institute, Fiocruz, Rio de Janeiro, Brazil

    X
  • Mina C. Hosseinipour,

    Affiliation: Kamuzu Central Hospital, Lilongwe, Malawi

    X
  • Johnstone Kumwenda,

    Affiliation: Department of Medicine, College of Medicine, Blantyre, Malawi

    X
  • Umesh Lalloo,

    Affiliation: Nelson R. Mandela School of Medicine, Durban, South Africa

    X
  • Cynthia Riviere,

    Affiliation: Institut Nacional de laboratoire et de Recherches, Port-au-Prince, Haiti

    X
  • Jorge Sanchez,

    Affiliation: Asociación Civil Impacta Salud y Educación, Lima, Peru

    X
  • Marineide Melo,

    Affiliation: Servico de Infectology, Hospital Nossa Senhora da Conceicao-GHC, Porto Alegre, Brazil

    X
  • Khuanchai Supparatpinyo,

    Affiliation: Department of Medicine and Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand

    X
  • Srikanth Tripathy,

    Affiliation: National AIDS Research Institute, Pune, India

    X
  • Ana I. Martinez,

    Affiliation: National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Apsara Nair,

    Affiliation: Frontier Science & Technology Research Foundation, Amherst, Massachusetts, United States of America

    X
  • Ann Walawander,

    Affiliation: Frontier Science & Technology Research Foundation, Amherst, Massachusetts, United States of America

    X
  • Laura Moran,

    Affiliation: Social & Scientific Systems, Inc, Silver Spring, Maryland, United States of America

    X
  • Yun Chen,

    Affiliation: Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, United States of America

    X
  • Wendy Snowden,

    Affiliation: GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

    X
  • James F. Rooney,

    Affiliation: Gilead Sciences, Inc., Foster City, California, United States of America

    X
  • Jonathan Uy,

    Affiliation: Bristol-Myers Squibb Company, Plainsboro, New Jersey, United States of America

    X
  • Robert T. Schooley,

    Affiliation: University of California San Diego, San Diego, United States of America

    X
  • Victor De Gruttola,

    Affiliation: Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, United States of America

    X
  • James Gita Hakim, for the PEARLS study team of the ACTG,

    Affiliation: University of Zimbabwe College of Health Sciences, Harare, Zimbabwe

    X
  • Edith Swann

    Membership of the AIDS Clinical Trials Group PEARLS Team is provided in the Acknowledgments.

    X
  • Published: August 14, 2012
  • DOI: 10.1371/journal.pmed.1001290

Reader Comments (0)

Post a new comment on this article